<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03404843</url>
  </required_header>
  <id_info>
    <org_study_id>16-6361H</org_study_id>
    <nct_id>NCT03404843</nct_id>
  </id_info>
  <brief_title>Red Blood Cell ATP Release and Vascular Function in Humans</brief_title>
  <official_title>Red Blood Cell ATP Release and Vascular Function in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colorado State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Colorado State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous work demonstrates that the red blood cells of older adults do not release a potent
      vasodilator (ATP) as well as the red blood cells of younger adults. The investigators are
      targeting a pathway within the red blood cell using fasudil hydrochloride to determine if
      both the release of ATP from red blood cells and blood flow responses to low oxygen (hypoxia)
      and exercise in older adults can be improved.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will initiate contact with the investigators by responding to flyers placed in
      the community either by phone or email. The first correspondence (phone or email) will
      provide a brief description of the research and ask a series of screening questions to
      determine age, height, weight, and any medications participants may be taking as well as the
      current health status (diagnoses, basic health history, and physical activity level) of
      participants. If they qualify, a two hour screening visit is scheduled during a time when the
      participant will be examined by the physician. All participants will undergo informed consent
      in a face to face private meeting with the research coordinator. Following informed consent,
      participants will be evaluated by a physician and undergo a treadmill stress test to rule out
      cardiovascular disease.

      During the study, heart rate will be monitored with a 3-lead ECG and blood pressure will be
      monitored noninvasively with a blood pressure cuff on the finger (finometry). Venous blood
      will be collected at multiple time points via a catheter inserted into a forearm vein
      draining skeletal muscle circulation for measurement of blood gases (0.5 mL/sample) and
      plasma [ATP] (2 mL/sample), with less than 100 mL of blood being drawn in total (~60mL
      total). Blood flow at rest and in response to hypoxia and exercise will be measured
      non-invasively using Doppler ultrasound of the brachial artery. Hypoxia trials will be
      performed by having participants breathe a low oxygen gas mixture via a mouthpiece that is
      hooked up to gas tanks and an anesthesia monitor to decrease their oxygen saturation to ~80%
      (similar to hiking a 14er) for 10 minutes. Exercise trials will last for approximately 15
      minutes and will involve participants performing graded-intensity rhythmic handgrip exercise
      by lifting weights (corresponding to a low, moderate, and high workload) using a pulley
      system. The drug treatment used in this study (fasudil) is being given because it may improve
      red blood cell ATP release in older adults. This is a double-blinded placebo controlled
      study, thus participation will occur on two randomized experimental days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 14, 2017</start_date>
  <completion_date type="Actual">October 5, 2018</completion_date>
  <primary_completion_date type="Actual">October 5, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a randomized, double-blind, placebo-controlled, crossover study. Approximately 20 young and 20 older adults will be recruited for participation and randomly assigned to either a placebo (saline) infusion or a fasudil hydrochloride infusion. The dose of fasudil hydrochloride is 60 mg/ 60 min.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>A person not associated with any data collection or data analysis is randomizing the treatment and preparing it in a separate room. All data is collected as visit 1 or visit 2.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Forearm Blood Flow Responses to Hypoxia After Administration of Intervention</measure>
    <time_frame>Within 4 hours after administration of intervention</time_frame>
    <description>Forearm blood flow measured using Doppler ultrasound before and after 5 minutes of exposure to hypoxia (breathing a mix of low-oxygen gas and room air to achieve oxygen saturations of ~80%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forearm Blood Flow Responses to Exercise After Administration of Intervention</measure>
    <time_frame>Within 4 hours after administration of intervention</time_frame>
    <description>Forearm blood flow measured using Doppler ultrasound before and during continuous rhythmic handgrip exercise at a low, moderate, and high intensity workload (4 minutes at each workload for 12 minutes in total).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ATP Release to Hypoxia After Administration of Intervention</measure>
    <time_frame>Within 4 hours after administration of intervention</time_frame>
    <description>Venous plasma concentrations of ATP measured using a luminometer before and after 5 minutes of exposure to hypoxia (breathing a mix of low-oxygen gas and room air to achieve oxygen saturations of ~80%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ATP Release to Exercise After Administration of Intervention</measure>
    <time_frame>Within 4 hours after administration of intervention</time_frame>
    <description>Venous plasma concentrations of ATP measured using a luminometer before and during continuous rhythmic handgrip exercise at a low, moderate, and high intensity workload (4 minutes at each workload for 12 minutes in total).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial Stiffness After Administration of Intervention</measure>
    <time_frame>Immediately following administration of intervention</time_frame>
    <description>Arterial stiffness measured non-invasively using a SphygmoCor system after administration of saline (placebo) and fasudil. This is a randomized crossover design study, so participants will receive 1 treatment (saline or fasudil) on their first visit and the other treatment on their second visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Fasudil hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to measurements of vascular function and ATP release.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to measurements of vascular function and ATP release.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fasudil Hydrochloride</intervention_name>
    <description>10 mg/mL vial of fasudil hydrochloride. 6 mL (60 mg) of fasudil hydrochloride are added to a 100 mL saline bag for delivery to subjects.</description>
    <arm_group_label>Fasudil hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>100 mL saline bag.</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Sedentary to moderately active

          -  18 to 30 years old for young subjects

          -  60 to 80 years old for older subjects

        Exclusion Criteria:

          -  Obesity (BMI â‰¥ 30 kg/m^2)

          -  Cardiovascular disease

          -  Metabolic disease

          -  Use of medications that can influence cardiovascular function

          -  Blood pressure greater than or equal to 140/90

          -  Smoker

          -  Use of hormone replacement therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Dinenno, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Colorado State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Colorado State University, Dept. of Health and Exercise Science</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cvlab.colostate.edu/</url>
    <description>Lab website</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 7, 2017</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <results_first_submitted>February 9, 2020</results_first_submitted>
  <results_first_submitted_qc>February 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2020</results_first_posted>
  <last_update_submitted>February 23, 2020</last_update_submitted>
  <last_update_submitted_qc>February 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Colorado State University</investigator_affiliation>
    <investigator_full_name>Frank Dinenno</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasudil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03404843/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03404843/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fasudil, Then Saline</title>
          <description>Participants were randomized to receive a single 100 mL intravenous infusion of 60 mg fasudil hydrocholoride + saline in 60 minutes prior to measurements of vascular function and ATP release. After a washout period of at least 5 days, participants received a single 100 mL intravenous infusion of saline (placebo) in 60 minutes prior to measurements of vascular function and ATP release.</description>
        </group>
        <group group_id="P2">
          <title>Saline, Then Fasudil</title>
          <description>Participants were randomized to receive a single 100 mL intravenous infusion of saline (placebo) in 60 minutes prior to measurements of vascular function and ATP release. After a washout period of at least 5 days, participants received a single 100 mL intravenous infusion of 60 mg fasudil hydrocholoride + saline in 60 minutes prior to measurements of vascular function and ATP release.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study difficulties unrelated to Tx</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fasudil, Then Saline</title>
          <description>Participants were randomized to receive a single 100 mL intravenous infusion of 60 mg fasudil hydrocholoride + saline in 60 minutes prior to measurements of vascular function and ATP release. After a washout period of at least 5 days, participants received a single 100 mL intravenous infusion of saline (placebo) in 60 minutes prior to measurements of vascular function and ATP release.</description>
        </group>
        <group group_id="B2">
          <title>Saline, Then Fasudil</title>
          <description>Participants were randomized to receive a single 100 mL intravenous infusion of saline (placebo) in 60 minutes prior to measurements of vascular function and ATP release. After a washout period of at least 5 days, participants received a single 100 mL intravenous infusion of 60 mg fasudil hydrocholoride + saline in 60 minutes prior to measurements of vascular function and ATP release.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18-30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.9" spread="4.0"/>
                    <measurement group_id="B2" value="23.7" spread="1.6"/>
                    <measurement group_id="B3" value="24.3" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forearm Blood Flow Responses to Hypoxia After Administration of Intervention</title>
        <description>Forearm blood flow measured using Doppler ultrasound before and after 5 minutes of exposure to hypoxia (breathing a mix of low-oxygen gas and room air to achieve oxygen saturations of ~80%).</description>
        <time_frame>Within 4 hours after administration of intervention</time_frame>
        <population>All participants who completed both interventions (crossover design) with outcome data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Young Saline</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to outcome measurements</description>
          </group>
          <group group_id="O2">
            <title>Young Fasudil</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to outcome measurements</description>
          </group>
          <group group_id="O3">
            <title>Older Saline</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to outcome measurements</description>
          </group>
          <group group_id="O4">
            <title>Older Fasudil</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to outcome measurements</description>
          </group>
        </group_list>
        <measure>
          <title>Forearm Blood Flow Responses to Hypoxia After Administration of Intervention</title>
          <description>Forearm blood flow measured using Doppler ultrasound before and after 5 minutes of exposure to hypoxia (breathing a mix of low-oxygen gas and room air to achieve oxygen saturations of ~80%).</description>
          <population>All participants who completed both interventions (crossover design) with outcome data collected</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="1.2"/>
                    <measurement group_id="O2" value="6.2" spread="1.2"/>
                    <measurement group_id="O3" value="2.1" spread="0.6"/>
                    <measurement group_id="O4" value="8.4" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within group comparison of treatment</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Within group comparison of treatment</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Forearm Blood Flow Responses to Exercise After Administration of Intervention</title>
        <description>Forearm blood flow measured using Doppler ultrasound before and during continuous rhythmic handgrip exercise at a low, moderate, and high intensity workload (4 minutes at each workload for 12 minutes in total).</description>
        <time_frame>Within 4 hours after administration of intervention</time_frame>
        <population>All participants who completed both interventions (crossover design) with outcome data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Young Saline</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to outcome measurements</description>
          </group>
          <group group_id="O2">
            <title>Young Fasudil</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to outcome measurements</description>
          </group>
          <group group_id="O3">
            <title>Older Saline</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to outcome measurements</description>
          </group>
          <group group_id="O4">
            <title>Older Fasudil</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to outcome measurements</description>
          </group>
        </group_list>
        <measure>
          <title>Forearm Blood Flow Responses to Exercise After Administration of Intervention</title>
          <description>Forearm blood flow measured using Doppler ultrasound before and during continuous rhythmic handgrip exercise at a low, moderate, and high intensity workload (4 minutes at each workload for 12 minutes in total).</description>
          <population>All participants who completed both interventions (crossover design) with outcome data collected</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315.4" spread="31.0"/>
                    <measurement group_id="O2" value="283.0" spread="25.4"/>
                    <measurement group_id="O3" value="255.3" spread="19.9"/>
                    <measurement group_id="O4" value="304.2" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within group comparison of treatment</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Within group comparison of treatment</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in ATP Release to Hypoxia After Administration of Intervention</title>
        <description>Venous plasma concentrations of ATP measured using a luminometer before and after 5 minutes of exposure to hypoxia (breathing a mix of low-oxygen gas and room air to achieve oxygen saturations of ~80%).</description>
        <time_frame>Within 4 hours after administration of intervention</time_frame>
        <population>All participants who completed both interventions (crossover design) with outcome data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Young Saline</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to outcome measurements</description>
          </group>
          <group group_id="O2">
            <title>Young Fasudil</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to outcome measurements</description>
          </group>
          <group group_id="O3">
            <title>Older Saline</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to outcome measurements</description>
          </group>
          <group group_id="O4">
            <title>Older Fasudil</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to outcome measurements</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ATP Release to Hypoxia After Administration of Intervention</title>
          <description>Venous plasma concentrations of ATP measured using a luminometer before and after 5 minutes of exposure to hypoxia (breathing a mix of low-oxygen gas and room air to achieve oxygen saturations of ~80%).</description>
          <population>All participants who completed both interventions (crossover design) with outcome data collected</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="10.5"/>
                    <measurement group_id="O2" value="5.3" spread="8.0"/>
                    <measurement group_id="O3" value="5.3" spread="5.4"/>
                    <measurement group_id="O4" value="17.4" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within group comparison of treatment</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Within group comparison of treatment</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in ATP Release to Exercise After Administration of Intervention</title>
        <description>Venous plasma concentrations of ATP measured using a luminometer before and during continuous rhythmic handgrip exercise at a low, moderate, and high intensity workload (4 minutes at each workload for 12 minutes in total).</description>
        <time_frame>Within 4 hours after administration of intervention</time_frame>
        <population>All participants who completed both interventions (crossover design) with outcome data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Young Saline</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to outcome measurements</description>
          </group>
          <group group_id="O2">
            <title>Young Fasudil</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to outcome measurements</description>
          </group>
          <group group_id="O3">
            <title>Older Saline</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to outcome measurements</description>
          </group>
          <group group_id="O4">
            <title>Older Fasudil</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to outcome measurements</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ATP Release to Exercise After Administration of Intervention</title>
          <description>Venous plasma concentrations of ATP measured using a luminometer before and during continuous rhythmic handgrip exercise at a low, moderate, and high intensity workload (4 minutes at each workload for 12 minutes in total).</description>
          <population>All participants who completed both interventions (crossover design) with outcome data collected</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" spread="16.8"/>
                    <measurement group_id="O2" value="42.2" spread="15.1"/>
                    <measurement group_id="O3" value="28.4" spread="7.9"/>
                    <measurement group_id="O4" value="46.2" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within group comparison of treatment</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Within group comparison of treatment</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arterial Stiffness After Administration of Intervention</title>
        <description>Arterial stiffness measured non-invasively using a SphygmoCor system after administration of saline (placebo) and fasudil. This is a randomized crossover design study, so participants will receive 1 treatment (saline or fasudil) on their first visit and the other treatment on their second visit.</description>
        <time_frame>Immediately following administration of intervention</time_frame>
        <population>All participants who completed both interventions (crossover design) with outcome data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Young Saline</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to outcome measurements</description>
          </group>
          <group group_id="O2">
            <title>Young Fasudil</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to outcome measurements</description>
          </group>
          <group group_id="O3">
            <title>Older Saline</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to outcome measurements</description>
          </group>
          <group group_id="O4">
            <title>Older Fasudil</title>
            <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to outcome measurements</description>
          </group>
        </group_list>
        <measure>
          <title>Arterial Stiffness After Administration of Intervention</title>
          <description>Arterial stiffness measured non-invasively using a SphygmoCor system after administration of saline (placebo) and fasudil. This is a randomized crossover design study, so participants will receive 1 treatment (saline or fasudil) on their first visit and the other treatment on their second visit.</description>
          <population>All participants who completed both interventions (crossover design) with outcome data collected</population>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="0.2"/>
                    <measurement group_id="O2" value="5.2" spread="0.2"/>
                    <measurement group_id="O3" value="7.8" spread="0.4"/>
                    <measurement group_id="O4" value="7.6" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Within group comparison of treatment</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Within group comparison of treatment</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During study visits and 1 month after (as reported by participants)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Young Saline</title>
          <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to outcome measurements</description>
        </group>
        <group group_id="E2">
          <title>Young Fasudil</title>
          <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to outcome measurements</description>
        </group>
        <group group_id="E3">
          <title>Older Saline</title>
          <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to outcome measurements</description>
        </group>
        <group group_id="E4">
          <title>Older Fasudil</title>
          <description>Participants received a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to outcome measurements</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Frank Dinenno</name_or_title>
      <organization>Colorado State University</organization>
      <phone>970-491-3203</phone>
      <email>frank.dinenno@colostate.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

